Search Within

Avni Mukund Desai

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (6)
Groups
  1. Biostatistics Service (6)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (6)
  3. Center for Pancreatic Cancer Research (6)
  4. Department of Medicine (6)
  5. Department of Pathology and Laboratory Medicine (6)
  6. Epidemiology and Biostatistics (6)

More Groups

People
  1. David Ilson (4)
  2. David Solit (4)
  3. Geoffrey Ku (4)
  4. Joanne Chou (4)
  5. Laura Tang (4)
  6. Marinela Capanu (4)

More People

Years
  1. 2025 (1)
  2. 2023 (2)
  3. 2020 (1)
  4. 2019 (2)
Publications
  1. Nature (2)
  2. Clinical Cancer Research (1)
  3. Gastric Cancer (1)
  4. Lancet Oncology (1)
  5. The Oncologist (1)
Publishers
  1. Nature Publishing Group (2)
  2. American Association for Cancer Research (1)
  3. Elsevier Science, Inc. (1)
  4. Oxford University Press (1)
  5. Springer (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
    Journal Article

    Sethna, Z.; Guasp, P.; Reiche, C.; Milighetti, M.; Ceglia, N.; Patterson, E.; Lihm, J.; Payne, G.; Lyudovyk, O.; Rojas, L. A.; more...
    Nature (2025)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
    Journal Article

    Rojas, L. A.; Sethna, Z.; Soares, K. C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Regorafenib in combination with first-line chemotherapy for metastatic esophagogastric cancer
    Journal Article

    Moy, R. H.; Dos Santos Fernandes, G.; Jonsson, P.; Chou, J. F.; Basunia, A.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer
    Journal Article

    Won, E.; Basunia, A.; Chatila, W. K.; Hechtman, J. F.; Chou, J. F.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
    Journal Article

    Mondaca, S.; Margolis, M.; Sanchez-Vega, F.; Jonsson, P.; Riches, J. C.; Ku, G. Y.; Hechtman, J. F.; Tuvy, Y.; Berger, M. F.; Shah, M. A.; more...
    Gastric Cancer (2019)

    Fulltext@MSK | Save